ArticleBMC cancer2020

Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study.

Masahiro Kondo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.